دورية أكاديمية
Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials.
| العنوان: | Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials. |
|---|---|
| المؤلفون: | Biesma HD; Department of Pathology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Soeratram TTD; Department of Pathology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Sikorska K; Department of Biometrics, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Caspers IA; Department of Pathology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.; Department of Gastrointestinal Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., van Essen HF; Department of Pathology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Egthuijsen JMP; Department of Pathology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Mookhoek A; Department of Pathology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., van Laarhoven HWM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., van Berge Henegouwen MI; Department of Surgery, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Nordsmark M; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., van der Peet DL; Department of Surgery, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands., Warmerdam FARM; Department of Medical Oncology, Zuyderland Hospital, Sittard, The Netherlands., Geenen MM; Department of Medical Oncology, OLVG, Amsterdam, The Netherlands., Loosveld OJL; Department of Medical Oncology, Amphia Hospital, Breda, The Netherlands., Portielje JEA; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Los M; Department of Medical Oncology, St. Antonius Hospital, Nieuwegein, The Netherlands., Heideman DAM; Department of Pathology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Meershoek-Klein Kranenbarg E; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands., Hartgrink HH; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands., van Sandick J; Department of Surgery, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Verheij M; Department of Radiation Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., van de Velde CJH; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands., Cats A; Department of Gastrointestinal Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Ylstra B; Department of Pathology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., van Grieken NCT; Department of Pathology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. nct.vangrieken@amsterdamumc.nl. |
| المصدر: | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association [Gastric Cancer] 2022 May; Vol. 25 (3), pp. 640-651. Date of Electronic Publication: 2022 Feb 07. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 100886238 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1436-3305 (Electronic) Linking ISSN: 14363291 NLM ISO Abbreviation: Gastric Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Tokyo : Springer-Verlag Tokyo, c1998- |
| مواضيع طبية MeSH: | Epstein-Barr Virus Infections* , Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/genetics , Stomach Neoplasms*/surgery, Clinical Trials as Topic ; Herpesvirus 4, Human/genetics ; Humans ; Microsatellite Instability ; Neoadjuvant Therapy ; Prognosis |
| مستخلص: | Background: Epstein-Barr virus positivity (EBV+) and microsatellite instability (MSI-high) are positive prognostic factors for survival in resectable gastric cancer (GC). However, benefit of perioperative treatment in patients with MSI-high tumors remains topic of discussion. Here, we present the clinicopathological outcomes of patients with EBV+, MSI-high, and EBV-/MSS GCs who received either surgery only or perioperative treatment. Methods: EBV and MSI status were determined on tumor samples collected from 447 patients treated with surgery only in the D1/D2 trial, and from 451 patients treated perioperatively in the CRITICS trial. Results were correlated to histopathological response, morphological tumor characteristics, and survival. Results: In the D1/D2 trial, 5-year cancer-related survival was 65.2% in 47 patients with EBV+, 56.7% in 47 patients with MSI-high, and 47.6% in 353 patients with EBV-/MSS tumors. In the CRITICS trial, 5-year cancer-related survival was 69.8% in 25 patients with EBV+, 51.7% in 27 patients with MSI-high, and 38.6% in 402 patients with EBV-/MSS tumors. Interestingly, all three MSI-high tumors with moderate to complete histopathological response (3/27, 11.1%) had substantial mucinous differentiation. No EBV+ tumors had a mucinous phenotype. 115/402 (28.6%) of EBV-/MSS tumors had moderate to complete histopathological response, of which 23/115 (20.0%) had a mucinous phenotype. Conclusions: In resectable GC, MSI-high had favorable outcome compared to EBV-/MSS, both in patients treated with surgery only, and in those treated with perioperative chemo(radio)therapy. Substantial histopathological response was restricted to mucinous MSI-high tumors. The mucinous phenotype might be a relevant parameter in future clinical trials for MSI-high patients. (© 2022. The Author(s).) |
| References: | J Surg Oncol. 2018 Apr;117(5):829-839. (PMID: 29534305) Ann Oncol. 2016 Sep;27(suppl 5):v38-v49. (PMID: 27664260) Ann Surg Oncol. 2013 Oct;20(11):3407-13. (PMID: 23943026) Histopathology. 2018 May;72(6):965-973. (PMID: 29220097) Acta Pathol Microbiol Scand. 1965;64:31-49. (PMID: 14320675) Br J Cancer. 2013 May 28;108(10):1978-84. (PMID: 23652310) Nature. 2014 Sep 11;513(7517):202-9. (PMID: 25079317) JAMA Oncol. 2017 Sep 01;3(9):1197-1203. (PMID: 28241187) Methods Mol Biol. 2012;838:329-41. (PMID: 22228020) Ann Surg Oncol. 2010 Jun;17(6):1471-4. (PMID: 20180029) Gastric Cancer. 1998 Mar;1(2):125-133. (PMID: 11957056) Lancet Oncol. 2016 Dec;17(12):1697-1708. (PMID: 27776843) N Engl J Med. 2006 Jul 6;355(1):11-20. (PMID: 16822992) Cancer Commun (Lond). 2019 Mar 29;39(1):13. (PMID: 30922401) Ann Oncol. 2019 Dec 1;30(12):1914-1924. (PMID: 31613312) BMC Cancer. 2021 Oct 23;21(1):1138. (PMID: 34688251) Gastric Cancer. 2002;5(4):208-12. (PMID: 12491078) Gastric Cancer. 2020 Nov;23(6):951-960. (PMID: 32514646) Lancet Oncol. 2010 May;11(5):439-49. (PMID: 20409751) J Clin Oncol. 2004 Feb 15;22(4):664-70. (PMID: 14966089) Ann Surg Oncol. 2016 Mar;23(3):943-50. (PMID: 26530444) J Clin Oncol. 2019 Dec 10;37(35):3392-3400. (PMID: 31513484) Lancet Oncol. 2018 May;19(5):616-628. (PMID: 29650363) Pathol Oncol Res. 2016 Jan;22(1):197-202. (PMID: 26502923) J Pathol Clin Res. 2019 Oct;5(4):227-239. (PMID: 31206244) Lancet Oncol. 2020 Feb;21(2):204. (PMID: 32007194) Gastric Cancer. 2019 Jul;22(4):785-792. (PMID: 30617648) Lancet. 2020 Aug 29;396(10251):635-648. (PMID: 32861308) Lancet Oncol. 2020 Feb;21(2):203. (PMID: 32007193) Am J Surg Pathol. 2011 Jan;35(1):127-34. (PMID: 21164296) Oncol Lett. 2016 May;11(5):2959-2964. (PMID: 27123046) CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593) Breast. 2012 Jun;21(3):289-95. (PMID: 22277312) Science. 2007 Nov 16;318(5853):1108-13. (PMID: 17932254) Cancer. 1994 Jun 1;73(11):2680-6. (PMID: 8194005) Lancet. 2019 May 11;393(10184):1948-1957. (PMID: 30982686) ESMO Open. 2019 May 27;4(3):e000470. (PMID: 31231566) Int J Surg. 2014 Oct;12(10):1123-6. (PMID: 25072703) |
| فهرسة مساهمة: | Keywords: Epstein–Barr virus (EBV); Histopathological response; Microsatellite instability (MSI); Mucinous differentiation; Stomach neoplasms |
| تواريخ الأحداث: | Date Created: 20220207 Date Completed: 20220419 Latest Revision: 20220716 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC9013342 |
| DOI: | 10.1007/s10120-022-01280-2 |
| PMID: | 35129727 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1436-3305 |
|---|---|
| DOI: | 10.1007/s10120-022-01280-2 |